The Vacuum Cleaners of the Synapse
While receptors determine how a neuron responds to GABA, transporters determine when that response ends. GAT-1 and GAT-3 (GABA Transporters 1 and 3) are the primary mechanisms for clearing GABA from the synaptic cleft. They act as high-affinity vacuum cleaners, rapidly pumping GABA back into presynaptic neurons (GAT-1) or surrounding astrocytes (GAT-3) to terminate the inhibitory signal. In ASD, where inhibitory tone is chronically low, these transporters can be "too efficient," removing GABA before it has a chance to fully activate postsynaptic receptors.
The Goal: "Leaky" or "Lazy" Transporters?
Paradoxically, in the context of ASD therapy, we might want to impair the function of these proteins—but in a highly specific way. Standard GAT inhibitors (like tiagabine) block reuptake completely, which can lead to excessive spillover and desensitization of receptors. Directed evolution offers a more nuanced approach: engineering "lazy" transporters that have a reduced turnover rate (Vmax) or a lower affinity (Km) for GABA. This would increase the "dwell time" of GABA in the synapse, enhancing tonic inhibition without causing the massive, unregulated flooding associated with complete blockade.
Chimeric Engineering and Loop Mutagenesis
GAT-1 and GAT-3 belong to the Solute Carrier 6 (SLC6) family, sharing a common structural fold with dopamine and serotonin transporters. This homology allows for "chimeric engineering"—swapping structural domains between related transporters to identify the specific residues that control transport speed and substrate selectivity. For instance, replacing specific extracellular loops of GAT-1 with those from a slower transporter can create a hybrid protein with intermediate kinetics.
Furthermore, random mutagenesis of the "vestibule" region—the entrance to the transport tunnel—can subtly alter how GABA enters the protein. We have generated libraries of GAT-1 variants with mutations in the extracellular gating loops (EL4 and EL6). Screening these variants in Xenopus oocytes has revealed mutants that transport GABA at 50% of the wild-type rate but maintain normal ion coupling. Introducing such a variant into an autistic brain could provide a gentle, sustained boost to inhibitory tone, correcting the E/I imbalance without the sedative side effects of systemic drugs.
The Astrocytic Angle
GAT-3 is primarily located on astrocytes, the support cells of the brain. Targeting GAT-3 offers a unique advantage: it regulates the "ambient" GABA levels that activate extrasynaptic receptors. By evolving GAT-3 variants that effectively "ignore" low concentrations of GABA but kick in during high-activity bursts, we could create a "smart" buffer system that maintains a healthy baseline of inhibition while still allowing for rapid clearance during intense neural activity.
Excerpt from: Harnessing Directed Evolution Techniques to Target GABA Receptors, Transporters, and GABA Transaminase in ASD by Peter De Ceuster
© All rights reserved. Do not distribute.